November 30, 2016 - By Louis Casey
The financial firm Aegis Capital has started coverage on NuVasive (NASDAQ:NUVA)‘s stock, rating it a Buy while giving it the TP at $72.00.
Out of 14 analysts covering Nuvasive Inc. (NASDAQ:NUVA), 12 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 86% are positive. $74 is the highest target while $56 is the lowest. The $65.08 average target is -0.43% below today’s ($65.36) stock price. Nuvasive Inc. has been the topic of 20 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Barclays Capital upgraded NuVasive, Inc. (NASDAQ:NUVA) on Friday, May 27 to “Overweight” rating. The firm has “Outperform” rating given on Tuesday, October 6 by BMO Capital Markets. The firm has “Buy” rating given on Tuesday, September 1 by Leerink Swann. Canaccord Genuity upgraded the stock to “Buy” rating in Tuesday, October 6 report. Jefferies maintained NuVasive, Inc. (NASDAQ:NUVA) rating on Wednesday, July 27. Jefferies has “Buy” rating and $72 price target. The rating was upgraded by Bank of America on Friday, December 11 to “Neutral”. Cowen & Co maintained the stock with “Outperform” rating in Wednesday, April 27 report. The stock of NuVasive, Inc. (NASDAQ:NUVA) earned “Outperform” rating by Northland Capital on Thursday, July 30. The stock of NuVasive, Inc. (NASDAQ:NUVA) has “Buy” rating given on Tuesday, September 22 by UBS. JP Morgan upgraded the shares of NUVA in a report on Wednesday, July 13 to “Overweight” rating.
About 238,589 shares traded hands. NuVasive, Inc. (NASDAQ:NUVA) has risen 20.23% since April 27, 2016 and is uptrending. It has outperformed by 15.00% the S&P500.
Analysts await NuVasive, Inc. (NASDAQ:NUVA) to report earnings on February, 9. They expect $0.50 EPS, up 42.86% or $0.15 from last year’s $0.35 per share. NUVA’s profit will be $25.70M for 32.69 P/E if the $0.50 EPS becomes a reality. After $0.40 actual EPS reported by NuVasive, Inc. for the previous quarter, Wall Street now forecasts 25.00% EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.51 in 2016 Q2. Its up 0.40, from 1.11 in 2016Q1. The ratio increased, as 37 funds sold all NuVasive, Inc. shares owned while 77 reduced positions. 45 funds bought stakes while 82 increased positions. They now own 50.84 million shares or 1.81% more from 49.94 million shares in 2016Q1.
Principal Fincl Gru Incorporated, a Iowa-based fund reported 360,941 shares. Springbok Cap Limited Com holds 0% or 128 shares in its portfolio. The California-based Aperio Limited Com has invested 0% in NuVasive, Inc. (NASDAQ:NUVA). Bancorp Of Montreal Can last reported 0% of its portfolio in the stock. Gemmer Asset Mngmt Lc owns 97 shares or 0% of their US portfolio. Moreover, Blackrock Ltd has 0.02% invested in NuVasive, Inc. (NASDAQ:NUVA) for 231,338 shares. Shelton Mgmt, a California-based fund reported 4,118 shares. Bogle Limited Partnership De holds 0.09% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 20,638 shares. Moreover, Blackrock Fund has 0.04% invested in NuVasive, Inc. (NASDAQ:NUVA) for 3.38M shares. Alyeska Investment Group L P accumulated 959,029 shares or 0.59% of the stock. Moreover, Brown Brothers Harriman & Com has 0% invested in NuVasive, Inc. (NASDAQ:NUVA) for 100 shares. Arrowgrass Ptnrs (Us) L P holds 263,120 shares or 0.17% of its portfolio. Cornerstone Capital Management Limited Liability Corp holds 0% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 6,800 shares. Paradigm Capital Ny last reported 15,400 shares in the company. Moreover, Seven Eight Lc has 0.15% invested in NuVasive, Inc. (NASDAQ:NUVA) for 7,300 shares.
Insider Transactions: Since June 15, 2016, the stock had 4 insider buys, and 5 insider sales for $322,731 net activity. Shares for $170,100 were sold by Hannon Jason. On Monday, October 31 the insider OHALLERAN MICHAEL D bought $250,071. On Monday, August 1 HOWE LESLEY H sold $224,909 worth of the stock or 3,602 shares. Miles Patrick had bought 16,967 shares worth $1.00 million. 5,000 NuVasive, Inc. (NASDAQ:NUVA) shares with value of $298,400 were bought by Stafslien Joan.
Nuvasive, Inc. is a medical device company in the spine market. The company has a market cap of $3.36 billion. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. It has a 82.95 P/E ratio. The Firm offers two product lines: spine surgery products and biologics.
According to Zacks Investment Research, “NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company’s current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.”
Nuvasive, Inc., incorporated on July 21, 1997, is a medical device firm in the spine market. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Firm offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.
More news for NuVasive, Inc. (NASDAQ:NUVA) were recently published by: Fool.com, which released: “Weaker Sales Guidance Pushes NuVasive, Inc. Lower by 10%” on October 26, 2016. Fool.com‘s article titled: “NuVasive, Inc. Is Taking Market Share and the CEO Isn’t Afraid to Tout It” and published on August 03, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey